Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Recognized for Leadership in Clean Technology and Global ... 11 Solazyme, Inc., a,leading algal biotechnology company, ... as one of the GoingGreen 100 Top Private ... was compiled by the,AlwaysOn editorial panel. In order ...
... 11 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... Marcial of BusinessWeek, highlighted Access Pharmaceuticals in ... The article is also available,on http://www.BusinessWeek.com ... The article focused upon the major ...
... 11 Archer Daniels,Midland Company (NYSE: ... Company,s,Commercial and Production group which is responsible ... John Rice, executive,vice president, Commercial and Production, ... business goals. I am confident that,these individuals ...
Cached Biology Technology:Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner 2Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner 3Access Highlighted in Recent BusinessWeek Article 2ADM Announces Appointments 2ADM Announces Appointments 3
(Date:4/15/2014)... the Women,s Health Initiative (WHI) shows no significant connection ... was published online today in Menopause , the ... analyzed the relationship between the blood levels of vitamin ... flashes, night sweats, sleep disturbance, concentration, and forgetfulness in ... D WHI trial. , There was good reason to ...
(Date:4/15/2014)... for nearly all life on Earth, yet many aspects ... is known about how it is regulated in response ... not know the full list of the parts of ... , , A type of single-cell green algae called ... photosynthesis research. Despite its importance in the research world, ...
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
Breaking Biology News(10 mins):Low Vitamin D may not be a culprit in menopause symptoms 2Goddard scientist receives Vega Medal from King of Sweden 2
... MANHATTAN, Kan. -- Those choices at the pump may look ... University research team is conducting a study that could eventually ... early August, four faculty members from Kansas State University,s College ... from the U.S. departments of Agriculture and Energy under the ...
... (August 17, 2011) 23andMe, Inc., a leading personal ... a list of associations curated by the National Human ... demonstrating that self-reported medical data is effective and reliable ... in the journal PLoS ONE establish 23andMe,s ...
... University scientist studying human bone growth has received a ... to study a chemical compound with potential to fight ... professor of biomedical engineering at Indiana University-Purdue University Indianapolis ... at the IU School of Medicine, will investigate the ...
Cached Biology News:Harnessing the power of plants 2Harnessing the power of plants 323andMe replicates over 180 genetic associations with Web-based research platform 2New compound may accelerate bone healing, prevent osteoporosis 2New compound may accelerate bone healing, prevent osteoporosis 3
... optimized cell lines in combination with the ... Nucleofector Kits are only functional in combination ... can be transfected with this kit. The ... brackets in percent (Efficiency [%] / viability ...
Canine Chondrocytes (CnC) (500,000 cells)...
... Workstation brings together UV irradiation and antimicrobial ... against PCR contamination! Quickly inactivate DNA ... a clean environment with antimicrobial coated stainless ... within minutes with built-in 30-minute timer ...
B-FABP (FL-132)...
Biology Products: